Form 8-K AbbVie Inc. For: Jul 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
BMO Capital Keeps AbbVie (ABBV) at 'Market Perform'; Says Humira Solid in Q2, but Questions Remain
July 29, 2016 11:54 AM EDTBMO Capital affirms AbbVie (NYSE: ABBV) at Market Perform with a price target of $66 following Q2 results out earlier Friday.
Analyst Alex Arfaei commented, revenue was 3.7% above consensus, driven by higher sales of Humira and Imbruvica, while OPEX was... More
